Blog Financial Times: Get vaccine new variant ready January 13, 2021 GreenLight Biosciences explain to the Financial Times how messenger RNA can help get the Covid-19 vaccine new variant ready. GreenLight Biosciences spoke to the Financial Times about making sure that any vaccine is new variant ready for Covid-19. An extract from the article is below: Andrey Zarur, chief executive of Greenlight Biosciences, a biotech company that is making a messenger RNA vaccine, said it made sense to design new vaccines to “prepare for further drift”.“Then you have a better chance of your new vaccine continuing to protect against new variants,” Mr Zarur said. Read the full article here. Find out more about how GreenLight manufactures RNA here. More of Greenlight Bioscience in the news: The Economist: RNA for Bees and Crops GenEdge: GreenLight Strives for Global RNA Equity The National: Africa needs to be self-reliant in vaccine production Amin Khan welcomed as Chief Scientific Officer, Human Health Financial Times: How to vaccinate the world GreenLight partners with Fraunhofer IME